Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 May 2024 Status changed from not yet recruiting to recruiting.
- 27 Mar 2024 Planned initiation date changed from 15 Mar 2024 to 1 Apr 2024.
- 23 Feb 2024 Planned initiation date changed from 1 Feb 2024 to 15 Mar 2024.